IS1903B - 2-methýl-thíenó-bensódíasepín, samsetning til inntöku - Google Patents

2-methýl-thíenó-bensódíasepín, samsetning til inntöku

Info

Publication number
IS1903B
IS1903B IS4565A IS4565A IS1903B IS 1903 B IS1903 B IS 1903B IS 4565 A IS4565 A IS 4565A IS 4565 A IS4565 A IS 4565A IS 1903 B IS1903 B IS 1903B
Authority
IS
Iceland
Prior art keywords
benzodiazepine
thieno
methyl
oral composition
oral
Prior art date
Application number
IS4565A
Other languages
English (en)
Other versions
IS4565A (is
Inventor
R. Cochran George
Morris Tommy
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1903(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of IS4565A publication Critical patent/IS4565A/is
Publication of IS1903B publication Critical patent/IS1903B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS4565A 1995-03-24 1997-09-22 2-methýl-thíenó-bensódíasepín, samsetning til inntöku IS1903B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
IS4565A IS4565A (is) 1997-09-22
IS1903B true IS1903B (is) 2003-11-20

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4565A IS1903B (is) 1995-03-24 1997-09-22 2-methýl-thíenó-bensódíasepín, samsetning til inntöku

Country Status (46)

Country Link
US (4) US5919485A (is)
EP (2) EP1093815B1 (is)
JP (1) JPH11502848A (is)
KR (1) KR100408172B1 (is)
CN (1) CN1178662C (is)
AP (1) AP679A (is)
AR (2) AR002720A1 (is)
AT (3) ATE206924T1 (is)
AU (1) AU696601B2 (is)
BG (1) BG62594B1 (is)
BR (1) BR9607791A (is)
CA (1) CA2216372C (is)
CH (1) CH691217A5 (is)
CO (1) CO4700474A1 (is)
CR (1) CR5278A (is)
CZ (1) CZ296007B6 (is)
DE (3) DE69615887T2 (is)
DK (3) DK1093815T3 (is)
EA (1) EA000938B1 (is)
EE (1) EE03551B1 (is)
EG (1) EG24077A (is)
ES (2) ES2232379T3 (is)
FI (1) FI973749A0 (is)
GB (1) GB2313783B (is)
HU (1) HU225269B1 (is)
IL (1) IL117611A (is)
IS (1) IS1903B (is)
LT (1) LT4350B (is)
LU (1) LU90115B1 (is)
LV (1) LV11983B (is)
MY (1) MY113440A (is)
NO (1) NO320388B1 (is)
NZ (1) NZ306111A (is)
OA (1) OA10511A (is)
PE (1) PE44997A1 (is)
PL (1) PL188316B1 (is)
PT (2) PT1093815E (is)
RO (1) RO118370B1 (is)
SE (1) SE9703206D0 (is)
SI (3) SI1093815T1 (is)
SK (1) SK283745B6 (is)
TR (1) TR199701018T1 (is)
TW (1) TW426526B (is)
UA (1) UA44766C2 (is)
WO (1) WO1996029995A1 (is)
ZA (1) ZA962338B (is)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
WO2003101997A1 (en) 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) * 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
WO2005034921A1 (en) * 2003-10-07 2005-04-21 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ATE511512T1 (de) 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
BRPI0610780A2 (pt) * 2005-04-22 2016-09-06 Teva Pharma formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
AU2006253006B8 (en) * 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
JP4938006B2 (ja) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
DE602006014030D1 (de) * 2006-07-05 2010-06-10 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CN101983055B (zh) * 2008-01-31 2013-05-08 杏林制药株式会社 以咪达那新为有效成分的口腔内速崩片的制造方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR20120093060A (ko) * 2009-03-25 2012-08-22 카이틴, 아이엔씨. 초음파 냉각 시스템
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
CN105658209A (zh) * 2013-09-13 2016-06-08 拜耳制药股份公司 含有瑞法美替的药物组合物
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
CN117085022A (zh) * 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
US20010018071A1 (en) 2001-08-30
DK109097A (da) 1997-11-12
MY113440A (en) 2002-02-28
CZ296007B6 (cs) 2005-12-14
DE69615887D1 (de) 2001-11-22
GB2313783B (en) 1998-11-18
CN1178662C (zh) 2004-12-08
LT4350B (lt) 1998-05-25
ATA902296A (de) 1999-02-15
PT1093815E (pt) 2005-03-31
SI9620041A (sl) 1998-06-30
BG62594B1 (bg) 2000-03-31
KR19980703189A (ko) 1998-10-15
HUP9800410A3 (en) 2000-01-28
EG24077A (en) 2008-05-11
EA000938B1 (ru) 2000-06-26
IS4565A (is) 1997-09-22
RO118370B1 (ro) 2003-05-30
PL188316B1 (pl) 2005-01-31
EP1093815B1 (en) 2004-12-15
EP0733367A1 (en) 1996-09-25
OA10511A (en) 2002-04-24
HU225269B1 (en) 2006-08-28
ATE284695T1 (de) 2005-01-15
ES2164837T3 (es) 2002-03-01
FI973749A (fi) 1997-09-22
NO974363L (no) 1997-11-17
SI0733367T1 (en) 2002-06-30
LV11983B (en) 1998-07-20
GB2313783A (en) 1997-12-10
DK1093815T3 (da) 2005-04-25
BG101901A (en) 1998-10-30
TW426526B (en) 2001-03-21
US5919485A (en) 1999-07-06
NO320388B1 (no) 2005-11-28
NZ306111A (en) 1999-02-25
KR100408172B1 (ko) 2004-02-18
AP9701064A0 (en) 1997-10-31
CA2216372A1 (en) 1996-10-03
EA199700260A1 (ru) 1998-02-26
AU5428096A (en) 1996-10-16
IL117611A (en) 2002-05-23
DK173323B1 (da) 2000-07-24
DE69634053D1 (de) 2005-01-20
BR9607791A (pt) 1998-07-07
AR002720A1 (es) 1998-04-29
WO1996029995A1 (en) 1996-10-03
CH691217A5 (de) 2001-05-31
AT405606B (de) 1999-10-25
LU90115B1 (fr) 1997-09-10
CN1179102A (zh) 1998-04-15
PE44997A1 (es) 1997-10-23
EE9700328A (et) 1998-06-15
DK0733367T3 (da) 2001-11-26
AU696601B2 (en) 1998-09-17
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
ATE206924T1 (de) 2001-11-15
GB9719817D0 (en) 1997-11-19
TR199701018T1 (xx) 1998-01-21
AR001405A1 (es) 1997-10-22
HUP9800410A2 (hu) 1998-07-28
LT97149A (en) 1998-01-26
EP0733367B1 (en) 2001-10-17
US6780433B2 (en) 2004-08-24
FI973749A0 (fi) 1997-09-22
SE9703206L (sv) 1997-09-05
MX9707186A (es) 1997-11-29
CZ300197A3 (en) 1997-12-17
EE03551B1 (et) 2001-12-17
CO4700474A1 (es) 1998-12-29
DE69615887T2 (de) 2002-04-11
NO974363D0 (no) 1997-09-22
DE69634053T2 (de) 2005-12-22
UA44766C2 (uk) 2002-03-15
LV11983A (lv) 1998-03-20
AP679A (en) 1998-09-28
SE9703206D0 (sv) 1997-09-05
CR5278A (es) 1996-07-04
IL117611A0 (en) 1996-07-23
US6190698B1 (en) 2001-02-20
CA2216372C (en) 2007-11-20
SI1093815T1 (en) 2005-06-30
ES2232379T3 (es) 2005-06-01
US20050085462A1 (en) 2005-04-21
DE19681287T1 (de) 1998-03-19
US7229643B2 (en) 2007-06-12
EP1093815A1 (en) 2001-04-25
JPH11502848A (ja) 1999-03-09
SK283745B6 (sk) 2003-12-02
ZA962338B (en) 1997-09-22
PT733367E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
DZ2026A1 (fr) Compositions vaccinantes.
DZ2055A1 (fr) Compositions vaccinantes.
TR199501447A2 (tr) Oral bilesimler.
ID20233A (id) Komposisi oral
FI974241A0 (fi) BPM-15 -koostumukset
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
BR9506536A (pt) Composição oral
BR9607058A (pt) Composição
BR9606809A (pt) Composição inseticidamente ativa
NO981568D0 (no) Randtennings-tennsatssammensetninger
DE69617029D1 (de) Organoton-zusammensetzungen
TR199501650A2 (tr) Agiz bilesimleri.
DK1023035T3 (da) Mundplejemiddel
PT728814E (pt) Composicao betuminosa
ID20466A (id) Komposisi oral
TR199501645A2 (tr) Agiz bilesimleri.
BR9609903A (pt) ComposiçÃo inseticidamente ativa
DE69616374T2 (de) Germizide zusammensetzung
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
TR199601012A2 (tr) Sampuan terkibi.
BR9606974A (pt) Composições orais
ID19246A (id) Komposisi oral antikalkulus
DE69603228D1 (de) Aluminoxanate-Zusammensetzungen
ATE206150T1 (de) Farbstoffstabilisierte zusammensetzungen